Dark

Check out our Dark Pool Levels

FULC
Fulcrum Therapeutics, Inc. Common Stock
stock NASDAQ

At Close

Jul 21, 2026 3:59:57 PM EDT

3.69USD+1.934%(+0.07)1,512,879

3.68Bid 3.69Ask 0.01Spread

Pre-market

Jul 21, 2026 9:20:30 AM EDT

3.63USD+0.276%(+0.01)1,964

After-hours

Jul 21, 2026 4:59:30 PM EDT

3.69USD0.000%(0.00)142,303

OverviewOptionsHistoricalExchangesShortsTrends

FULC Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

FULC Specific Mentions

As of Jul 22, 2026 12:46:38 AM EDT (1 min. ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

36 days ago • u/Embarrassed_Care_321 • r/biotech_stocks • can_anyone_name_any_recent_biotech_stock_success • C

I've had success with stocks like VRNA, VERA and FULC at different stages in their cycles and am currently invested in LRMR and OSTX. Heres my criteria:
1. MUST have positive phase 2 data in an unmet need. Phase 1 and 2 are gambling, once the positive data is in, yeah you missed the first move but you also missed the dilution.
2. Ensure the FDA and said biotech are ALLIGNED with ENDPOINTS. Alot of these CRL come from misalignment on endpoints. LRMR is aligned with FDA on surrogate endpoint of skin frataxin levels and OSTX on OS/EFS, big part of my thesis.
3. P values , P values, P values. Is it actually the drug that's producing the positive results?
4. Is there an unmet need, if not does the drug actually move the goalpost? If your drug is to treat high cholesterol well it better be more effective and safer than statins.
5. Cash runway.
I track the FDA PDUFA calendar and I study every CRL that comes in. Gather the reasoning and drill it against your investments to see if there are vulnerabilities.

36 days ago • u/Embarrassed_Care_321 • r/biotech_stocks • can_anyone_name_any_recent_biotech_stock_success • C

I've had success with stocks like VRNA, VERA and FULC at different stages in their cycles and am currently invested in LRMR and OSTX. Heres my criteria:
1. MUST have positive phase 2 data in an unmet need. Phase 1 and 2 are gambling, once the positive data is in, yeah you missed the first move but you also missed the dilution.
2. Ensure the FDA and said biotech are ALLIGNED with ENDPOINTS. Alot of these CRL come from misalignment on endpoints. LRMR is aligned with FDA on surrogate endpoint of skin frataxin levels and OSTX on OS/EFS, big part of my thesis.
3. P values , P values, P values. Is it actually the drug that's producing the positive results?
4. Is there an unmet need, if not does the drug actually move the goalpost? If your drug is to treat high cholesterol well it better be more effective and safer than statins.
5. Cash runway.
I track the FDA PDUFA calendar and I study every CRL that comes in. Gather the reasoning and drill it against your investments to see if there are vulnerabilities.

Share